Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Virtual Booth

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

DIGITAL CONTENT

2 NEWS #PharmaBuzz

media
2 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Bms-820836, Liafensine [usan], 1198790-53-2, R34id086z6, Liafensine (usan), Liafensine [usan:inn]

Molecular Formula

C₂₄H₂₂N₄

Molecular Weight

366.5 g/mol

InChI Key

VCIBGDSRPUOBOG-QFIPXVFZSA-N

FDA UNII

R34ID086Z6

Liafensine is under investigation in clinical trial NCT00892840 (Multiple-Ascending Dose Study).

1 2D Structure

Liafensine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-[(4S)-2-methyl-4-naphthalen-2-yl-3,4-dihydro-1H-isoquinolin-7-yl]pyridazin-3-amine

2.1.2 InChI

InChI=1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1

2.1.3 InChI Key

VCIBGDSRPUOBOG-QFIPXVFZSA-N

2.1.4 Canonical SMILES

CN1CC(C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4

2.1.5 Isomeric SMILES

CN1C[C@H](C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4

2.2 Other Identifiers

2.2.1 UNII

R34ID086Z6

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

2. Bms-820836

2.3.2 Depositor-Supplied Synonyms

1. Bms-820836

2. Liafensine [usan]

3. 1198790-53-2

4. R34id086z6

5. Liafensine (usan)

6. Liafensine [usan:inn]

7. Unii-r34id086z6

8. Bms 820836

9. Liafensine [inn]

10. Liafensine [who-dd]

11. Schembl1120067

12. Chembl2364614

13. Dtxsid60152610

14. Chebi:177531

15. Bdbm50459930

16. Db14878

17. D10443

18. Q18353685

19. (5)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

20. (s)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

21. 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

22. 6-[(4s)-2-methyl-4-naphthalen-2-yl-3,4-dihydro-1h-isoquinolin-7-yl]pyridazin-3-amine

23. 3-pyridazinamine, 6-((4s)-1,2,3,4-tetrahydro-2-methyl-4-(2-naphthalenyl)-7-isoquinolinyl)-

24. 6-((4s)-2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

2.4 Create Date

2012-08-19

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₂N₄
Molecular Weight	366.5 g/mol
XLogP3	3.7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	2
Exact Mass	366.18444672 g/mol
Monoisotopic Mass	366.18444672 g/mol
Topological Polar Surface Area	55 Å²
Heavy Atom Count	28
Formal Charge	0
Complexity	525
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1